These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21074936)

  • 1. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
    Breccia M; Efficace F; Alimena G
    Cancer Lett; 2011 Jan; 300(2):115-21. PubMed ID: 21074936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies in controlling drug resistance.
    Frame D
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?
    Allen-Bard S
    Clin J Oncol Nurs; 2009 Oct; 13(5):537-42. PubMed ID: 19793710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of resistance to BCR-ABL kinase inhibitors].
    Diamond J; da Silva MG
    Acta Med Port; 2013; 26(4):402-8. PubMed ID: 24016650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic myeloid leukemia with imatinib mesylate.
    Ohno R
    Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of chronic myelogenous leukemia by using imatinib].
    Jinnai I
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
    [No Abstract]   [Full Text] [Related]  

  • 11. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
    Yeung DT; White DL
    Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
    [No Abstract]   [Full Text] [Related]  

  • 14. Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?
    Fava C; Saglio G
    Semin Hematol; 2010 Oct; 47(4):319-26. PubMed ID: 20875548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD; McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
    Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
    Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cultural factors related to adherence to imatinib in CML: a Mexican perspective.
    Cantú-Rodríguez OG; Sánchez-Cárdenas M; Gutiérrez-Aguirre CH; Jaime-Pérez JC; Mancias-Guerra C; González-Llano O; Gómez-Almaguer D
    Hematology; 2015 Mar; 20(2):72-6. PubMed ID: 25034734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.